Brad Tennis is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the antitrust practice. Brad's practice focuses on global government conduct investigations, antitrust litigation, and counseling, with a particular emphasis on emerging antitrust issues in high-technology sectors. Brad has represented clients in a number of landmark antitrust cases, including: Google in the FTC investigation that concluded with no enforcement action in 2013, Deutsche Telekom in the successful defense of the merger of T-Mobile and Sprint, and Google in the ongoing suits brought by the DOJ and State Attorneys General. He has represented clients in a broad range of industries, including software, telecommunications, computer and networking hardware, online advertising, internet infrastructure, physical security, pharmaceuticals, and media.
Brad Tennis is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the antitrust practice. Brad's practice focuses on global government conduct investigations, antitrust litigation, and counseling, with a particular emphasis on emerging antitrust issues in high-technology sectors. Brad has represented clients in a number of landmark antitrust cases, including: Google in the FTC investigation that concluded with no enforcement action in 2013, Deutsche Telekom in the successful defense of the merger of T-Mobile and Sprint, and Google in the ongoing suits brought by the DOJ and State Attorneys General. He has represented clients in a broad range of industries, including software, telecommunications, computer and networking hardware, online advertising, internet infrastructure, physical security, pharmaceuticals, and media.
Represented Hebei Welcome and North China Pharmaceutical Group in a successful appeal to the Second Circuit regarding price-fixing allegations and as respondents before the Supreme Court. The Second Circuit again found for Hebei Welcome and North China Pharmaceutical Group on remand.
Represented Hebei Welcome and North China Pharmaceutical Group in a successful appeal to the Second Circuit regarding price-fixing allegations and as respondents before the Supreme Court. The Second Circuit again found for Hebei Welcome and North China Pharmaceutical Group on remand.
Co-reporter, “Presidential Transition Report: The State of Antitrust Enforcement,” American Bar Association, February 5, 2021
Co-reporter, “Presidential Transition Report: The State of Antitrust Enforcement,” American Bar Association, February 5, 2021